Neuphoria Therapeutics Files 10-Q for Q2 2024

TL;DR

Neuphoria's Q2 10-Q is in. Check financials and ops updates.

AI Summary

Neuphoria Therapeutics Inc. filed its 10-Q for the period ending December 31, 2024. The company reported financial results and provided updates on its business operations. Key financial figures and operational highlights are detailed within the filing, offering insight into the company's performance and strategic direction.

Why It Matters

This filing provides investors and stakeholders with a crucial update on Neuphoria Therapeutics' financial health and operational progress, impacting investment decisions and market perception.

Risk Assessment

Risk Level: medium — As a biotechnology company, Neuphoria Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 0.000463 — EPS (Earnings per share for the period)
• 2024-12-31 — Reporting Period End (Indicates the end date for financial reporting)
• 2025-02-14 — Filing Date (Date the report was submitted to the SEC)

Key Players & Entities

• Neuphoria Therapeutics Inc. (company) — Filer of the 10-Q
• 2024-12-31 (date) — End of the reporting period
• 2025-02-14 (date) — Filing date
• BIONOMICS LIMITED/FI (company) — Former company name
• Dr Spyros Papapetropoulos (person) — Mentioned in relation to specific activities

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share NEUP The Nasdaq

Filing Documents

• neup-20241231.htm (10-Q) — 1694KB
• neup-ex31_1.htm (EX-31.1) — 20KB
• neup-ex31_2.htm (EX-31.2) — 19KB
• neup-ex32_1.htm (EX-32.1) — 10KB
• neup-ex32_2.htm (EX-32.2) — 12KB
• 0000950170-25-020473.txt ( ) — 6524KB
• neup-20241231.xsd (EX-101.SCH) — 873KB
• neup-20241231_htm.xml (XML) — 1021KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) 2 Condensed Consolidated Statement of Changes in Shareholders' Equity 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 23 PART II. OTHER INFORMATION 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30

Signatures

Signatures 32 i Basis of Presentation Neuphoria Therapeutics Inc. is a Delaware corporation ("Neuphoria") listed on the Nasdaq Global Market. We were formally known as Bionomics Limited ("Bionomics") an Australian company that on October 1, 2024 entered into a Scheme Implementation Agreement with Neuphoria to re-domicile from Australia to the State of Delaware pursuant to a Scheme of Arrangement under Australian law. On December 23, 2024, the re-domiciliation of Bionomics was implemented and effectuated in accordance with the Scheme Implementation Agreement, as amended. As a result, (i) holders of ordinary shares of Bionomics received one share of our common stock for every 2,160 ordinary shares of Bionomics held on the Scheme record date; (ii) holders of Bionomics' American Depositary Shares (or "ADS"), with each ADS representing 180 ordinary shares of Bionomics, received one share of Neuphoria's common stock for every 12 ADSs held on the Scheme record date; and (iii) we became the successor issuer to Bionomics. Prior to our redomiciliation, since July 1, 2024, we had been reporting as a domestic U.S. issuer on SEC Forms 10-K, 10-Q, and 8-K. The terms "we," "our," "us" and the "Company" in this Quarterly Report on Form 10-Q refer to Neuphoria Therapeutics Inc. and its consolidated subsidiaries after December 23, 2024 and Bionomics and its consolidated subsidiaries on and prior to December 23, 2024, unless otherwise specified. When we refer to "you," we mean the potential holders of the applicable series of securities: "shares" or "ordinary shares" refers to our ordinary shares prior to December 23, 2024; shares of common stock refers to our common stock, par value $0.00001 per share beginning December 24, 2024; "ADSs" refers to American Depositary Shares, each of which represented 180 ordinary shares prior to December 23, 2024; and "ADRs" refers to American Depositary Receipts, which evidence the ADSs. We use our registered and unregistered trad

—F INANCIAL INFORMATION

PART I—F INANCIAL INFORMATION

Cond ensed Consolidated Financial Statements

Item 1. Cond ensed Consolidated Financial Statements. Neuphoria Therapeutics Inc. Condensed Cons olidated Balance Sheets (Unaudited) December 31, June 30, 2024 2024 Assets Current assets: Cash and cash equivalents $ 4,344,578 $ 12,608,109 Accounts receivable, non-trade 35,561 126,884 Prepaid insurance expense 18,469 458,765 Total current assets 4,398,608 13,193,758 Property and equipment, net 1,683 1,994 Intangible assets, net 5,136,157 5,467,522 Operating lease right-of-use assets 150,519 216,975 Restricted cash 73,982 78,826 Goodwill 8,407,271 8,690,018 Total assets $ 18,168,220 $ 27,649,093 Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 1,530,667 $ 2,243,662 Accrued expenses and other current liabilities 484,515 1,463,421 Operating lease liability 118,492 121,990 Total current liabilities 2,133,674 3,829,073 Operating lease liability, net of current portion 49,818 117,628 Contingent consideration 580,298 587,762 Deferred tax liability 842,921 963,540 Accompanying warrants liability 810,125 4,657,832 Other non-current liabilities 3,389 2,886 Total liabilities 4,420,225 10,158,721 Commitments and contingencies (Note 16) Shareholders' equity: Common stock, $ 0.00001 par value, 1,628,659 and 1,103,954 shares issued and outstanding at December 31, 2024 and June 30, 2024, respectively 16 11 Additional paid-in capital 198,189,833 198,481,027 Accumulated other comprehensive loss, net of tax ( 3,716,647 ) ( 3,013,595 ) Accumulated deficit ( 180,725,207 ) ( 177,977,071 ) Total shareholders' equity 13,747,995 17,490,372 Total liabilities and shareholders' equity $ 18,168,220 $ 27,649,093 The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. 1 Neuphoria Therapeutics Inc. Condensed Conso

View Full Filing

View this 10-Q filing on SEC EDGAR